Popular Posts: This Single-Digit Stock Could Soar Through the Roof in 2014Buy Fallen Miners for Huge (Eventual) Upside2 Commercial REITs Building on Solid Foundations Recent Posts: Regional Banks Are Expecting to Catch Fire in 2014 This Single-Digit Stock Could Soar Through the Roof in 2014 2 Commercial REITs Building on Solid Foundations View All Posts
At long last the new year is upon us, and I am more excited about the trade of the decade than ever before. Now that we have a clearer picture of all the new regulations and how they will impact the small regional and community bank I think we will see merger activity pick up in the sector.
Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood. Its lead product, lomitapide has completed pivotal Phase III clinical trial to treat patients with a rare inherited lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The company also plans to develop lomitapide for the treatment of adult patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion: - [By MONEYMORNING.COM]
Aegerion PharmaceuticalsInc. (Nasdaq: AEGR) developed a drug, Juxtapid, for a rare genetic condition called homozygous familial hypercholesterolemia, or HoFH, that can raise a person's cholesterol levels to more than 1,000 mg/dL. A healthful level is considered to be less than 200 mg/dL. The disease largely affects kids, who can die of heart attack by age 2. Most are dead by age 11. When Juxtapid hit the market, it was the only therapy available. ISIS Pharmaceuticals Inc. (Nasdaq: ISIS) would soon join in the competition with its less expensive injectable drug, Kynamro, but Juxtapid had fewer side effects and could be administered orally.
- [By Garrett Cook]
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from ZELTIQ Aesthetics (NASDAQ: ZLTQ) and Aegerion Pharmaceuticals (NASDAQ: AEGR).
- [By Garrett Cook]
Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from ZELTIQ Aesthetics (NASDAQ: ZLTQ) and Aegerion Pharmaceuticals (NASDAQ: AEGR).
Best Regional Bank Companies To Own In Right Now: Western Digital Corp (WDC)
Western Digital Corporation (WD) is a provider of solutions for the collection, storage, management, protection and use of digital content, including audio and video. Its principal products are hard drives, which are devices that use one or more rotating magnetic disks (magnetic media) to store and allow access to data. Its hard drives are used in desktop and notebook computers, corporate and cloud computing data centers, home entertainment equipment and stand-alone consumer storage devices. In addition to hard drives, its other products include solid-state drives and home entertainment and networking products. The Company operates as the parent company of its hard drive business, Western Digital Technologies, Inc. Effective March 8, 2012, the Company acquired Viviti Technologies Ltd. In May 2012, the Company completed the divestiture of certain 3.5-inch hard drive assets to Toshiba Corporation. As part of its deal with Toshiba, WD also completed its purchase of Toshiba Storage Device (Thailand) Company Limited (TSDT), which manufactured hard drives.
The Company offers a line of storage devices. Its hard drives include 3.5-inch and 2.5-inch form factors, capacities ranging from 80 gigabytes to three terabytes, nominal rotation speeds up to 10,000 revolutions per minute, and interfaces, such as Serial Advanced Technology Attachment (SATA) and Serial Attached SCSI (Small Computer System Interface) (SAS). In addition, the Company offers a family of hard drives specifically designed to consume less power than standard drives, utilizing its WD GreenPower Technology. Its solid-state drives include 2.5-inch and Compact Flash form factors, capacities ranging from 1 gigabyte to 256 gigabytes, and interfaces, such as SATA and PATA.
Client Compute Storage Products
Client compute consists of hard drives and solid-state drives for desktop and mobile personal computers (PC��). During the fiscal year ended July 1, 2011 (fiscal 2011), it shipped 151 million hard drive clie! nt compute unit. Its client compute storage products include WD Caviar, WD Scorpio and WD Silicon Edge. WD Caviar family of hard drives is designed for use in desktop PCs. WD Scorpio family of hard drives is designed for use in mobile PCs. WD Silicon Edge family of solid-state drives is designed for both read-intensive client/consumer applications and write-intensive original equipment manufacturer (OEM) applications.
Client Non-Compute Storage Products
Client non-compute consists of branded products and consumer electronics products. Its hard drive client non-compute unit shipments were 46 million, during fiscal 2011.
Branded Products
Branded products consists of hard drives embedded into WD-branded external storage appliances with capacities ranging from 250 gigabytes to 8 terabytes and using interfaces, such as Universal Serial Bus (USB) 2.0, USB 3.0, external SATA, FireWire and Ethernet network connections. Certain branded products models include software that assists customers with back up, remote access and management of digital content. Branded products also include its home entertainment and networking products. Its branded products include My Book and WD Elements Desktop family of storage appliances. My Passport and WD Elements Portable family of storage appliances include WD ShareSpace, WD TV and WD Livewire.
My Book and WD Elements Desktop family of storage appliances are designed to add external capacity to desktops and digital video recorders (DVRs), allow for the transfer and storage of videos directly from certain camcorders, and connect to networks to simplify storage for consumers. My Passport and WD Elements Portable family of storage appliances are designed for external portability weighing less than one-half of a pound and allow for the transfer and storage of videos directly from certain camcorders. WD ShareSpace is a network-attached storage system designed for home office or small office applications. WD TV m! edia play! ers connect to a user�� television or home theater system and play digital movies, music and photos from an integrated hard drive, network hard drives, any of its WD-branded external hard drives, other USB mass storage devices or content services accessed over the Internet. WD Livewire, which enables consumers to use their existing electrical outlets to extend Internet connections throughout the home.
Consumer Electronics Products
WD AV family of hard drives is designed for use in products, such as DVRs and audio and video applications. WD AV drives deliver the characteristics CE manufacturers.
Enterprise Storage Products
Enterprise consists of hard drives for traditional enterprise and nearline storage applications, as well as solid-state drives for embedded applications. Its hard drive enterprise unit shipments were 10 million, for fiscal 2011. Its enterprise storage products include WD S25 hard drive, WD VelociRaptor, WD RE and WD SiliconDrive. WD S25 hard drive is designed for mission-critical enterprise server and storage applications, such as data centers and data arrays. WD VelociRaptor hard drive is designed for enterprise server and storage applications. This hard drive is also used in the high-end desktop PC market for applications including gaming, servers and advanced computer-aided design/computer-aided manufacturing (CAD/CAM) systems. WD RE family of hard drives is designed for nearline storage enterprise applications. WD SiliconDrive family of solid-state drives features fast read/write speeds in high capacities and is designed for embedded system OEM applications.
The Company competes with Hitachi Global Storage Technologies, Intel Corporation, Micron Technology, Inc., Samsung Electronics Co. Ltd., Seagate Technology, STEC, Inc. and Toshiba Corporation.
Advisors' Opinion: - [By Alex Planes]
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does Western Digital (NASDAQ: WDC ) fit the bill? Let's take a look at what its recent results tell us about its potential for future gains.
Best Regional Bank Companies To Own In Right Now: Quest Diagnostics Inc (DGX)
Quest Diagnostics Incorporated (Quest Diagnostics), incorporated in 1990, is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. Its diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. On April 4, 2011, the Company acquired Athena Diagnostics (Athena). On May 17, 2011, the Company acquired Celera Corporation (Celera). In January 2012, the Company acquired S.E.D. Medical Laboratories. In December 2012, the Company sold all of the assets of OralDNA Labs salivary-diagnostics business to Access Genetics. Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. The Company provides interpretive consultation through the medical and scientific staff. The Company is a provider of clinical testing and the provider of risk assessment services for the life insurance industry. The Company also is a provider of testing for clinical trials and testing for drugs of abuse. In January 2012, it acquired S.E.D. Medical Laboratories. In December 2012, it sold all of the ! assets of OralDNA Labs salivary-diagnostics business to Access Genetics. In January 2013, the Company acquired the Worcester -based clinical outreach laboratory business of UMass Memorial Medical Center.
Clinical Testing
The Company is a commercial clinical testing company. Physicians use clinical tests to assist in the detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions. Clinical testing is generally categorized as clinical laboratory testing and anatomic pathology services. The Company offers customers the access to the test menu of clinical laboratory and anatomic pathology tests in the United States. Clinical laboratory testing generally is performed on whole blood, serum, plasma and other body fluids, such as urine, and specimens such as microbiology samples.
The Company is a provider of routine clinical testing, including testing for drugs of abuse. The Company performs routine testing through its network of laboratories and rapid response laboratories. The Company also performs routine testing at hospital laboratories that the Company manages. The Company operates laboratories round the clock. The majority of test results are delivered electronically. Routine tests measure various bodily health parameters, such as the functions of the kidney, heart, liver, thyroid and other organs. Commonly ordered tests include blood chemistries, including cholesterol levels; complete blood cell counts; urinalysis; pregnancy and other prenatal tests, and routine microbiology testing.
The Company is a provider of anatomic pathology services in the United States, through its AmeriPath, Dermpath Diagnostics and Quest Diagnostics brands. Anatomic pathology involves the diagnosis of cancer and other diseases and medical conditions through examination of tissue and cell samples taken from patients. The Company provides inpatient anatomic pathology and medical director services at hospitals throughout the country, and through ! its labor! atories. The Company provides a range of services to all anatomic pathology subspecialties. The Company provides integrated, reports that include both anatomic pathology and clinical pathology tests, enabling its pathologists to offer patients and physicians a complete analysis. The Company introduced the Leumeta family of tests for leukemia and lymphoma.
The Company is a provider in the United States of gene-based and esoteric testing. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. Commonly ordered esoteric tests include viral and bacterial detection tests, drug therapy monitoring tests, genetic tests, autoimmune panels and complex cancer evaluations. During the year ended December 31, 2011, it acquired Athena Diagnostics, a provider of neurology testing. Its esoteric laboratories provide reference testing services to physicians, academic medical centers, hospitals and other commercial laboratories. The Company also offers gene-based tests for the predisposition, diagnosis, treatment and monitoring of cancers. The Company develops tests at its laboratories, such as Quest Diagnostics Nichols Institute. It also develops techniques and services in anatomic pathology.
In 2011, the Company introduced its melanoma treatment selection mutation panel, which is designed to assist in the personalized selection of patient therapies. The Company introduced its thyroid cancer mutation panel, which assists in the diagnosis of thyroid cancer and aids physicians and surgeons as they plan surgery and other therapies to treat and attempt to cure thyroid cancer. During 2011, it enhanced its SureSwab Vaginosis/Vaginitis Plus test. The Company introduced Accutype IL28b, a test designed to aid in the prediction of patient response to peginterferon alpha-based therapy for treating hepatitis C virus infection. In 2011, it introduced testing for very long chain fatty acids, to assist in diagnosis and monitori! ng of inh! erited disorders of fatty acid metabolism. It also introduced high resolution chromosomal analysis testing with oligonucleotide microarrays to enhance its testing services in the pre-natal and post-natal genetics areas. During 2011, the Company released a test for therapeutic drug monitoring of dabigatran, an oral anti-coagulant. The Company also released genetic testing for SLC01B1, which helps identify patients at risk for myopathy from Simvastatin therapy for cholesterol reduction. Through Athena Diagnostics, it launched several molecular genetic tests for stroke, neuromuscular diseases and mitochondrial disorders.
Healthcare Information Technology
The Company provides interoperable technologies that help healthcare organizations and physicians enter, share and access clinical information without costly information technology (IT) implementation or workflow disruption, including through its Care360 suite of products and its ChartMaxx electronic document management system for hospitals. These solutions offer access to a national healthcare provider network, including approximately 200,000 networked physicians and clinicians using Quest Diagnostics��Care360 connectivity products. The Care360 products, including its Care360 Labs and Meds, enable physicians electronically to order diagnostic tests and review test results from Quest Diagnostics and electronically to prescribe medication. As of December 31, 2011, prescriptions were written through Care360 ePrescribing at an annualized rate of 32 million medications. Using its Care360 connectivity products, physicians can securely provide diagnostic and other data to a patient�� account. It offers Gazelle, a secure mobile health platform that allows users to receive their Quest Diagnostics laboratory results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone.
Clinical Trials Testing
The Company is a provider of central l! aboratory! testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. It has clinical trials testing centers in the United States and the United Kingdom, and it provides clinical trials testing in Argentina, Australia, Brazil, the People�� Republic of China and Singapore through affiliated laboratories. The Company has biomarker capabilities. In 2011, it acquired Celera, enhancing its ability to provide biomarker discovery and develop IVD test kits.
Life Insurer Services
The Company is a provider of risk assessment services to the life insurance industry in North America. It also provides risk assessment services for insurance companies doing business in many countries outside the United States. Its risk assessment services comprise underwriting support services to the life insurance industry, including laboratory testing, electronic data collection, specimen collection and paramedical examinations, medical record retrieval, case management, motor vehicle reports, telephone inspections, prescription histories and credit checks. The laboratory tests that it performs and data it gathers are designed to assist insurance companies to objectively evaluate the mortality risks of policy applicants. The majority of the testing is performed on specimens of life insurance applicants, but also includes specimens of applicants for other types of insurance. Most of its specimen collections and paramedical examinations are performed by its network of approximately 5,000 contracted paramedical examiners at the applicant�� home or workplace. The Company also offers paramedical examinations through approximately 500 of its patient service centers, and operate approximately 80 locations other than patient service centers in the United States and Canada where the Company provides paramedical examinations, bringing to approximately 580 the total number of sites where it can provide these examinations. The Company also contracts with third parties at over! an addit! ional 200 locations globally to coordinate providing these exams.
Employer Services
The Company is a provider of testing to employers for the detection of employee use of drugs of abuse. Its Quest Diagnostics Drug Testing Index, which is an annual report of its aggregate drug testing results, is used by employers, the federal government and the media to help identify and quantify drug abuse among the nation�� workforce. It provides a range of solutions for drugs of abuse, including urine, hair, blood and oral fluid tests. In 2011, it introduced Oral-Eze, its own oral fluid collection system that simplifies the collection of oral samples for routine drug testing. The Oral-Eze Oral Fluid Collector provides all the advantages of previous collection systems, with the added benefit of its indicator window technology. The Company provides wellness testing and analytic services to employers.
Diagnostic Products
Diagnostic Products include point-of-care, or near-patient and testing. The Company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including products for point-of-care, or near-patient, testing for the professional market. The Company has several companies, including Focus Diagnostics, HemoCue and Celera. Focus Diagnostics is a provider of infectious disease testing. Focus Diagnostics develops, manufactures and markets diagnostic products, such as HerpeSelect ELISA tests that detect patient antibodies to specific types of herpes simplex virus, which can be performed on a variety of instrument platforms. Focus Diagnostics sells its diagnostic products to academic medical centers, hospitals and commercial laboratories globally. Focus Diagnostics has an agreement with 3M Corporation for global human diagnostic rights to a compact integrated bench-top instrument for use with real time polymerase chain reaction (PCR) assays. These tests are sold under the Simplexa brand name. In 2011, Focus Diagnostic! s receive! d the CE mark to offer Simplexa tests in Europe, including tests for Cytomegalovirus, Epstein Barr virus, BK virus and clostridium difficile. Focus Diagnostics offers molecular transplant-testing menus in Europe.
HemoCue manufactures and distributes point-of-care testing products globally. HemoCue is a global provider in point-of-care testing for hemoglobin, with a growing market share for glucose, microalbumin and white blood cell testing. HemoCue offers its White Blood Cell Differential System in Europe. Celera offers complexity molecular diagnostic products in segments, such as HIV-1 drug resistance testing, reproductive genetics, transplantation and cardiovascular genetics. It also manufactures and offers the InSure fecal immunochemical test (FIT) for screening for colorectal cancer.
The Company competes with Laboratory Corporation of America Holdings, Inc.
Advisors' Opinion: - [By James E. Brumley]
Every year, more than 100,000 white papers on the topic of cancer and cancer treatments are published. Right now, there are over 500 new cancer drugs in development, and those therapies are part of more than 10,000 different clinical trials currently underway. That's all in addition to the already-approved cancer drugs, and the volumes of information we already know about oncology. What's it mean? It means the cancer-treating energy often suffers from information overload, which in turn means patients aren't getting the best care they could get. The solution is a tool built by a little company called CollabRx Inc. (NASDAQ:CLRX). The validation for that solution comes from much bigger companies Quest Diagnostics Inc. (NYSE:DGX) and Affymetrix, Inc. (NASDAQ:AFFX).
- [By John Udovich]
Small cap cancer diagnostic stock�Myriad Genetics, Inc (NASDAQ: MYGN) jumped to a five year high on Wednesday�thanks to good�news that the�government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should also mention that Myriad Genetics has been in our SmallCap Network Elite Opportunity (SCN EO) portfolio since early February and we are now up some 32.5% since then ��thanks in part to the shorts being put in a short squeeze.
- [By Mark Hulbert]
The stocks are C.H. Robinson Worldwide (CHRW) �, a freight-transportation company; chip maker Cirrus Logic (CRUS) �; independent oil company Forest Oil (FST) �; investment bank Greenhill & Co. (GHL) �; Intrepid Potash (IPI) �, a fertilizer company; retailer J.C. Penney (JCP) �; Quest Diagnostics (DGX) �, a medical diagnostic company; Strayer Education (STRA) �, a for-profit college; Tower Group International (TWGP) �, an insurance company; and Windstream Holdings (WIN) �, a rural telecommunications firm.
- [By Todd Campbell]
That could be particularly true for these three dividend-paying health-care companies: GlaxoSmithKline (NYSE: GSK ) , Merck (NYSE: MRK ) , and Quest Diagnostics (NYSE: DGX ) . They not only pay healthy dividend yields that can blunt the pain of a sell-off, but they're also strong performers during the coming quarter. That suggests investors may not want to sell them, and investors who have been considering them may want to step in and buy them.
Best Regional Bank Companies To Own In Right Now: News Corporation(NWS)
News Corporation operates as a diversified media company worldwide. Its Cable Network Programming segment produces and licenses news, business news, sports, general entertainment, and movie programming for distribution through cable television systems and direct broadcast satellite operators primarily in the United States, Latin America, Europe, and Asia. The company?s Filmed Entertainment segment produces and acquires live-action and animated motion pictures for distribution and licensing in entertainment media, as well as produces and licenses television programming worldwide. Its Television segment operates 27 broadcast television stations in the United States. The company?s Direct Broadcast Satellite Television segment distributes programming services via satellite and broadband directly to subscribers in Italy. Its Publishing segment provides newspapers and information services, such as publishing national newspapers in the United Kingdom, approximately 146 newspape rs in Australia, and a metropolitan and a national newspaper in the United States; book publishing services, including the publishing of English language books worldwide; and integrated marketing services comprising the publishing of free-standing inserts, which are marketing booklets containing coupons, rebates, and other consumer offers, as well as provides in-store marketing products and services, primarily to consumer packaged goods manufacturers in the United States and Canada. The company also sells advertising, sponsorships, and subscription services on the company?s various digital media properties and outdoor advertising space on various media primarily in Russia and eastern Europe; and provides data systems and professional services that enable teachers to use data to assess student progress and deliver individualized instructions. News Corporation was founded in 1922 and is headquartered in New York, New York.
Advisors' Opinion: - [By Chris Isidore]
In June, the former News Corp. took the name 21st Century Fox (FOX) and spun off its print publications such as the Wall Street Journal, the New York Post and several London newspapers into a new News Corp. (NWS)
- [By Reuters]
Warren is in the house.
- Warren Buffett (@WarrenBuffett) May 2, 2013 The handle wasn't officially verified by Twitter, but was confirmed by Fortune magazine, which hosted Buffett for a live webcast Thursday. It was billed as the first social media event for the notoriously technology-averse billionaire. If followers were dollars, Buffett is having even more success on Twitter than he had with one of his best investments ever, his 2008 stake in Goldman Sachs Group Inc. (GS). That deal gave him preferred stock that paid dividends at $900 a minute. On Twitter, he has gathered 1,000 followers a minute. By joining Twitter, the Berkshire Hathaway Inc. (BRK.B) chief executive officer now stands in good mogul company. Other relatively recent converts to the service include News Corp. (NWS) CEO Rupert Murdoch (@RupertMurdoch) and former U.S. President Bill Clinton (@BillClinton). - [By Sue Chang]
News Corp (NWS) :� The company owns HarperCollins Publishers, the publisher of J.R.R. Tolkein�� The Hobbit. The stock is up about 12% from June, when the old News Corp. split into two companies: News Corp and Twenty-First Century Fox, Inc. (FOX) �News Corp also owns MarketWatch, the publisher of this report.
